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Abstract
Background: Operational effectiveness of large-scale national programmes for the prevention of mother to child
transmission (PMTCT) of HIV in sub-Saharan Africa remains limited. We report on HIV-free survival among nine- to
24-month-old children born to HIV-positive mothers in the national PMTCT programme in Rwanda.
Methods: We conducted a national representative household survey between February and May 2009. Participants
were mothers who had attended antenatal care at least once during their most recent pregnancy, and whose
children were aged nine to 24 months. A two-stage stratified (geographic location of PMTCT site, maternal HIV
status during pregnancy) cluster sampling was used to select mother-infant pairs to be interviewed during
household visits. Alive children born from HIV-positive mothers (HIV-exposed children) were tested for HIV
according to routine HIV testing protocol. We calculated HIV-free survival at nine to 24 months. We subsequently
determined factors associated with mother to child transmission of HIV, child death and HIV-free survival using
logistic regression.
Results: Out of 1448 HIV-exposed children surveyed, 44 (3.0%) were reported dead by nine months of age. Of the
1340 children alive, 53 (4.0%) tested HIV positive. HIV-free survival was estimated at 91.9% (95% confidence interval:
90.4-93.3%) at nine to 24 months. Adjusting for maternal, child and health system factors, being a member of an
association of people living with HIV (adjusted odds ratio: 0.7, 95% CI: 0.1-0.995) improved by 30% HIV-free survival
among children, whereas the maternal use of a highly active antiretroviral therapy (HAART) regimen for PMTCT
(aOR: 0.6, 95% CI: 0.3-1.07) had a borderline effect.
Conclusions: HIV-free survival among HIV-exposed children aged nine to 24 months is estimated at 91.9% in
Rwanda. The national PMTCT programme could achieve greater impact on child survival by ensuring access to
HAART for all HIV-positive pregnant women in need, improving the quality of the programme in rural areas, and
strengthening linkages with community-based support systems, including associations of people living with HIV.
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Worldwide, 2.5 million children younger than 15 years
were living with HIV in 2009, and more than 90% had
been infected via mother to child transmission (MTCT)
of HIV during pregnancy, delivery and breastfeeding [1].
Developed countries have achieved remarkable progress
in the prevention of MTCT (PMTCT) by scaling up
access to highly active antiretroviral therapy (HAART),
elective caesarean section, and formula feeding as a
replacement to breastfeeding, leading to a dramatic
decrease in the MTCT rate (below 2%) [2-4]. Yet
MTCT remains a major challenge in developing coun-
tries, particularly in sub-Saharan Africa where more
than 90% of new paediatric HIV infections occur each
year [5-7].
Recent years have nonetheless seen remarkable
increases in the coverage of PMTCT programmes in
sub-Saharan Africa, with a growing number of countries
expanding access to comprehensive and more efficacious
PMTCT interventions. By December 2009, 22 countries
in sub-Saharan Africa had reported antiretroviral (ARV)
coverage rates of more than 50% for all HIV-positive
pregnant women, including 15 countries passing the
universal access target of 80% [8,9]. There is renewed
global commitment and increased financial support to
achieve the goal of elimination of vertical transmission
of HIV (an MTCT rate of less than 5% among all preg-
nant women living with HIV and a 90% reduction in
new paediatric HIV infections), with improved maternal,
n e w b o r na n dc h i l ds u r v i v a lb y2 0 1 5[ 1 0 ] .T h e2 0 1 0
World Health Organization’s( W H O ’s) revised guide-
lines for the use of ARV in pregnancy and breastfeeding
have provided an additional opportunity for sub-Saharan
Africa countries to significantly avert new HIV infec-
tions in infants while improving maternal and child
health and survival [11].
In 2010, WHO and the Inter Agency Task Team on
Prevention of HIV Infection in Pregnant Women,
Mothers and their Children outlined the strategic vision,
goals and global framework for countries to achieve
elimination of MTCT by 2015 [12,13]. Measuring the
effectiveness of national PMTCT programmes is a cor-
nerstone of this strategy. HIV-free survival was proposed
as the gold standard for measurement of PMTCT pro-
gramme effectiveness, as it captures direct effects (such
as HIV infection at birth and through breastfeeding,
deaths prevented and indirect benefits of PMTCT pro-
grammes) and indirect effects (survival benefits that may
accrue to HIV-exposed children who do not become
infected) of PMTCT [7]. Yet there is a paucity of data
on HIV-free survival rates measured at the level of the
national PMTCT programme. The effectiveness of
PMTCT depends not only on the efficacy of the ARV
interventions, but also on client- and health system-
related determinants of access and utilization of mater-
nal and child health interventions, such as of antenatal
care (ANC), facility-based delivery and post-natal care
[14-16].
Rwanda is located in eastern Africa, with more than
10 million inhabitants and a prevalence of HIV esti-
mated at 3% in the general population and 4.3% among
pregnant women. The Rwanda demographic and health
survey conducted in 2010 shows that 98% of all Rwan-
dan women who had live births between 2005 and 2010
attended at least one antenatal care visit.
An estimated 200,000 people are living with HIV,
among them 22,000 children younger than 15 years
[17]. The government of Rwanda aims at elimination of
MTCT as outlined in its 2008-2012 National Strategic
Plan for HIV&AIDS (NSP) response. The national
PMTCT programme has been established since 2001 by
the Ministry of Health through the Center for Treat-
ment and Research on AIDS, Tuberculosis, Malaria and
Other Epidemics (TRAC Plus), and 98% of all Rwandan
women who attended PMTCT services between 2006
and June 2010 accepted testing for HIV (Ministry of
Heath, TRAC Plus). However, i t se f f e c t i v e n e s sh a sn o t
yet been assessed. Recent studies have reported HIV-
free survival of 94-95% by nine months of age in a clini-
cal trial [18,19] and 95% by 12 to 18 months in district-
level PMTCT programme [20] in Rwanda. The present
study was initiated in 2009 to assess the effectiveness of
the Rwanda national PMTCT programme through the
measurement of nine- to 24-month HIV-free survival
and its determinants. This will serve as a baseline for
monitoring national trends toward achievements of the
NSP targets by 2012.
Methods
PMTCT programme description
After a successful pilot phase (1999) in one site (Kicu-
kiro health centre in Kigali), Rwanda established the
national PMTCT programme in 2001, coordinated by
the Treatment of Research on AIDS Center (TRAC
Plus) under the Ministry of Health. In 2006, Rwanda
developed and costed a national PMTCT scale-up plan
(2007-2012) with population-based targets that articu-
lated a comprehensive strategy to deliver a comprehen-
sive package of PMTCT interventions integrated within
MCH services at the community level. PMTCT pro-
gramme scale up and coordination is supported by var-
ious partners, including bilateral (Global Fund and
PEPFAR), multilateral (United Nations’ One UN Pro-
gramme) and civil society organizations. Routine provi-
sion of PMTCT services was effective in 75% of health
facilities in Rwanda by 2009 (up from 45% in 2005) [21],
and increasing number of male partners of pregnant
women were being tested for HIV (from 33% in 2005 to
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Page 2 of 1178% in 2009). Rwanda promotes the integration of
PMTCT services within routine maternal and child
health care, including family planning services.
In 2005, Rwanda transitioned from single-dose nevira-
pine (sd-NVP) to more efficacious ARV regimens for
PMTCT and rolled this out to all PMTCT sites by 2008
[22-25] (See Figure 1). Routine CD4 count screening
during pregnancy and services for early infant diagnosis
of HIV using dried blood spot tests were introduced. A
national task-shifting policy was instituted in 2009 to
support the effective initiation of HAART by nurses at
the decentralized level. By 2009, 61% of HIV-positive
pregnant women received ARV for PMTCT [26], and
about 92% of them received more efficacious ARV regi-
mens [26].
In November 2010, Rwanda adopted option B of the
recent WHO recommendations for use of ARVs in
PMTCT. This adoption permits all HIV-positive preg-
nant women to receive HAART, starting at different
stage of their pregnancy. Mothers who do not meet the
WHO for Affordable Feasible Accessible Safe and Sus-
tainable formula feeding (AFASS) criteria continue
ARVs throughout the entire breastfeeding period [11].
Study design
Study population and sampling methodology
This community-based household survey was conducted
between February and May 2009 and targeted mothers
(regardless of HIV status) who had previously attended
the PMTCT programme during their most recent preg-
nancy (at least one ANC visit), and their nine- to 24-
month-old children (born between March 2007 and
June 2008). A stratified two-stage cluster sampling pro-
cess was used to select participants. The first stage
included selection of a sample of PMTCT sites from a
stratified (urban vs. rural) sample of sites that had
offered PMTCT services for at least 36 months prior to
the survey. The second stage was done at the site level
using ANC registers; mothers across three strata were
selected: HIV-positive mothers who completed at least
four ANC visits; HIV-positive mothers who completed
less than four ANC visits; and HIV-negative mothers.
Assuming an MTCT rate of 35% and 25%, respectively,
without and with PMTCT programme available, a sig-
nificance level of 5%, a power of 80%, a non-response
rate of 10% and a design effect of 2, we estimated that
3420 mother-child pairs were required for the study’s
sample size. For this paper, we will focus on the HIV-
positive mothers.
Mother-child pairs identified in the clinic roster that
c o u l dn o tb ef o u n da tt h el o c a t i o ng i v e na st h e i rh o m e
place were replaced. Researchers returned to the health
facility and selected other mother-child pairs to com-
plete the total sample size. Very few mother-child pairs
could not be located. The replacement of missing pairs
did not cause underestimation of child mortality as the
only reason they could not be found was because the
address had been incorrectly documented or the pair
had moved.
Data collection
Household visits were conducted by a team composed
of one counsellor from the selected health facility, one
data collector and one laboratory technician. A standar-
dized and validated questionnaire was used to collect
data during interviews conducted in Kinyarwanda, the
national language of Rwanda. Each interview lasted on
average for 45 minutes. The questionnaire included
maternal knowledge of HIV in general and PMTCT in
particular, the use of PMTCT services by HIV-positive
women, and the use of reproductive health services.
Child demographics, anthropometric data and HIV sta-
tus were recorded in a separate tool.
At the time of the interview, the mother was asked if
the child was alive or deceased. If the child was
deceased, the mother was asked for the exact date when
her child had died. The time between birth and death
was recorded and thus was available for analysis. HIV
testing was done on the day of the interview. If the
child had died, the household visit stopped after the
questionnaire. The variable in follow-up time derives
from the computation of the time between birth and
death (if the child had died) or birth and interview date
(if the child was alive).
For children who did not survive, HIV infection status
was impossible to determine. If the child was alive, and
after obtaining informed verbal consent from parents, a
b l o o ds a m p l ew a sc o l l e c t e df r o ma l lH I V - e x p o s e dc h i l -
dren aged nine to 24 months using heel or finger prick.
We performed rapid HIV testing on the spot for all chil-
dren according to national HIV testing algorithm on
three parallel rapid tests: Determine (Abbott Labora-
tories, Abbott Park, IL) as the first test, Unigold (Trinity
Biotech) as confirmatory, and Capillus as a tie-breaker
in cases of discordancy between first and second test.
Scenario 1: HIV-positive pregnant women are considered medically eligible for 
lifelong“therapeutic” HAART (t-HAART) if they have WHO clinical stage 4 disease or 
a CD4 cell count of <350 cells/mm
3. Recommended regimens: zidovudine (AZT) or 
stavudine (d4T) +lamivudine (3TC) + nevirapine (NVP). 
Scenario 2: Women who present late (>34 weeks of gestation) are eligible for “short-
course” HAART (sc-HAART), irrespective of WHO staging or CD4 cell count. After 
delivery, HAARTis discontinued if the CD4 count is >350 cells/mm
3(with one-week 
AZT/3TC tail) or continued for lifeif the CD4 count is <350 cells/mm
3. Recommended 
regimen: AZT or d4T + 3TC + NVP. 
Scenario 3: Women not eligible for HAART receive short-course AZT (sc-AZT) after 
28weeks of gestation, plus SD-NVP at the onset of labour, with a one-week AZT/3TC 
tail.
Scenario 4: HIV-negative pregnant woman in discordant couple with an HIV-infected 
partner, as well as pregnant women testing HIV positive in the labour room, receive 
SD-NVP in labour with a one-week AZT/3TC tail. 
Scenario 5: Women receiving HAART at the time of conception continue ongoing 
treatment;efavirenz should be avoided in the first trimester. 
All babies receive SD-NVP at birth (within 72 hours) plus fourweeks of AZT syrup.
Figure 1 Scenarios.
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Page 3 of 11Polymerase chain reaction (PCR) was used to confirm
all HIV-positive rapid tests among children younger
than 18 months, and for indeterminate or discordant
results between the three rapid test results. In all other
cases, results of the three rapid tests were considered as
final. For quality control, every HIV rapid test batch was
checked for optimal performance using negative and
positive controls by the laboratory technician in the
field before the testing of the samples collected. One
out of every 20 samples tested with HIV rapid tests was
c o l l e c t e do nad r i e db l o o ds p o tc a r da n dr e t e s t e dw i t h
PCR. All PCR tests were performed at the National
Reference Laboratory in Kigali.
Ethical considerations
The study was approved by the National Institute of
Statistics of Rwanda and the Rwanda National Ethics
Committee. Appropriate measures were taken to ensure
survey participant protection, and informed consent of
mothers was secured prior to interview. Participation
was voluntary and patient confidentiality was ensured.
Data management and analysis
Completed questionnaires were periodically brought in
from the study sites to the School of Public Health of
the National University of Rwanda for data entry and
analysis. Data were entered using the Census and Survey
Processing System (CSPro 4.0). A quality control pro-
gramme was used to detect data collection and/or data
entry errors. This information was shared with field
teams during supervisory visits and weekly meetings to
improve data quality. In addition, 10% of the question-
naires were double entered for data quality control at
the initiation of data entry. Data was exported to
STATA 10.1 for data analysis. We focused only on data
from HIV-positive mothers and their HIV-exposed chil-
dren for this analysis.
Study endpoint
T h ep r i m a r ys t u d ye n d p o i n tw a sH I V - f r e es u r v i v a la t
nine to 24 months. Survival was defined as the probabil-
ity that the child was alive between nine and 24 months
of age, and tested HIV negative at this age.
Predictor variables
The potential predictor variables were divided into three
categories: individual, household variables and measures
of PMTCT of HIV interventions. Individual and house-
hold variables included socio-demographic characteris-
tics of mother and child, decision-making power about
health and nutrition index, decision-making power
about short- and long-term investment strategies index,
housing material index, household asset index, house-
hold size, access to clean water, and geographic location
of household. The measure of PMTCT interventions
included the type of ARV taken by mother and infant,
place of delivery, and infant feeding (whether or not the
infant was appropriately fed through the time of the
survey). Appropriate feeding options for HIV-exposed
children included at the time of the survey were: exclu-
sive breastfeeding from birth with early cessation of all
forms of breastfeeding by four to six months (early
weaning); or exclusive replacement from birth if AFASS
criteria are met.
Statistical analysis
We determined HIV-free survival as one minus the
combined risk of HIV infection and/or death. All con-
fidence intervals (CI) were at the 95% level of signifi-
cance, and p values of 0.05 were considered
statistically significant. We then modelled the risk of
H I Vi n f e c t i o nb yn i n et o2 4m o n t h sa n d / o rd y i n gb y
the age of nine months among children born to HIV-
positive mothers by logistic regression models. Step-
wise selection with a probability of 0.05 for variables
to enter the model and a probability of 0.15 to be
removed from the model was used to identify determi-
nants of either acquiring HIV infection and/or dying
among HIV-exposed children.
Results
Description of survey participants
The study was conducted in 105 health facilities in five
provinces. On average, 13.9 HIV-positive mother-child
pairs were interviewed per health facility, with a stan-
dard deviation of 8.2. We interviewed a total of 1434
HIV-positive mothers and their 1455 HIV-exposed chil-
dren (Figure 2). The mean age of HIV-positive mothers
interviewed was 32.2 years. The majority of women
lived in rural areas (80%), had a partner (69%), were
aged between 25 and 39 years (78%), and had a primary
school education level (68%) (Table 1). The majority of
children stopped exclusive breastfeeding at six months
(84%) and 91% at nine months, and were aged between
13 and 24 months (74%). (Table 2).
MotherͲchildpairs(n=3,020)
Mothersinterviewed(n=2,982)
HIVpositivemothers
(n=1,434;48%)
HIVnegativemothers
(n=1,548;52%)
HIVexposedchildren
(n=1,448)
HIVnonexposed
children(n=1,565)
HIVexposedchildren
dead(n=61;4.2%)
HIVexposedchildren
alive(n=1,387;95.8%)
HIVnonexposedchildren
alive(n=1,541;98.5%)
HIVnonexposedchildren
dead(n=24;1.5%)
HIVexposedchildren
deadby9months
(n=44;3.0%)
HIVexposedchildren
tested forHIV
(n=1,340;96.6%)
HIVpositivechildren
(n=53;4.0%)
Figure 2 Study overview.
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Page 4 of 11Distribution of ARV regimens for PMTCT among HIV-
positive mothers
Of the 1434 HIV-positive women interviewed, informa-
tion on the use of ARV or co-trimoxazole during preg-
nancy for PMTCT was not available for 101 (7.0%). Of
the 1333 (93.0%) women who reported the use of any
ARV or co-trimoxazole for PMTCT during pregnancy
(Table 1), 956 (72%) had received some ARV while 377
(28%) had not. ARV or co-trimoxazole received for
PMTCT included HAART (29%), dual ARV prophylaxis
(8%), sd-NVP (12%) and co-trimoxazole (21%).
HIV infection among children alive at age 9-24 months
and associated factors
Of the 1340 children alive aged nine to 24 months and
tested for HIV, 53 were positive, with an estimated HIV
prevalence of 4.0% (95% CI: 2.9-5.0). Maternal age was
the only factor associated with HIV infection among
Table 1 Background characteristics of HIV-positive mothers surveyed, Rwanda PMTCT programme, 2009
Characteristics Number %
Mother’s age groups (years), (n = 1430) 15-24 142 9.9
25-29 354 24.8
30-34 415 29.0
35-39 351 24.6
40-49 168 11.8
Mean age (years), 32.2
Marital status (n = 1429) Single/never married 122 8.5
Lives with a partner 986 69.0
Separated/divorced/widowed 321 22.5
Religion (n = 1432) No religion 23 1.5
Adventist 141 9.9
Catholic 609 42.5
Protestant 582 40.6
Muslim 60 4.2
Others 17 1.2
Education (n = 1428) Never attended school 353 24.7
Primary school 965 67.6
Vocational/technical 37 2.6
Secondary school 69 4.8
University 4 0.3
Literacy (n = 1431) can’t or have difficult reading and/or writing 573 40.04
can read but can’t or have difficult writing 69 4.82
can read and write easily 789 55.14
Residence (n = 1434) Rural 1141 79.6
Urban 293 20.4
Membership to a PLHIV association (n = 1417) Yes 775 54.7
No 642 45.3
ARV and/or cotrimoxazole received by mother (n = 1383) None 377 28.3
Cotrimoxazole 308 23.1
NVP alone 156 11.7
Dual therapy 108 8.1
Table 2 Background characteristics of children born from
HIV-positive mother, Rwanda PMTCT programme, 2009
Characteristics Number %
Child’s age (months) (n = 1357) < = 12 350 25.8
13-17 474 34.9
> = 18 533 39.3
Child’s sex (n = 1348) Female 719 49.65
Male 729 59.35
Feeding (n = 1360) Appropriate 117 8.6
Inappropriate 1,243 91.4
Month of breastfeeding (n = 1161) < = 6 973 83.8
7-9 84 7.2
10-12 41 3.5
> 12 63 5.4
Child received ARV at birth (n =
1394)
None 79 5.7
Nevirapine 536 38.5
Dual therapy 482 34.6
Don’t know 297 21.3
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Page 5 of 11children, with the highest HIV prevalence (6.8%) among
children born to young mothers (15 to 24 years) and
the lowest among children born to women aged 35 to
39 years (adjusted odds ratio [aOR]: 0.3, 95% CI: 0.1-
0.9) (Tables 3 and 4). In multivariate analysis, children
born to HIV-positive women who received HAART dur-
ing pregnancy were 60% less likely to be infected with
HIV when compared with children whose mothers did
not take any ARV during pregnancy (aOR: 0.4, 95% CI:
0.1-0.96) (Table 3).
HIV-free survival by 9-24 months and associated factors
Of 1455 children born to HIV-positive mothers, 61
(4.2%) were reported dead, including 44 (3.0%) by nine
months (Figure 2). Among 1340 children aged nine to
24 months who were alive and tested for HIV, 53 (4.0%)
tested HIV positive, translating into a nine- to 24-
month HIV-free survival rate of 91.9% (95% CI: 90.4-
93.3%) (Table 4). Children whose mothers were mem-
bers of a people living with HIV (PLHIV) association
(aOR: 0.7, 95% CI: 0.4-1.0.8) were 30% (aOR: 0.7, 95%
Table 3 Prevalence of HIV infection among HIV-exposed children by PMTCT programme indicators and maternal
demographic characteristics, Rwanda PMTCT programme, 2009
Characteristics HIV-positive children (%) Univariate analysis (p) Multivariate analysis
OR 95%CI
Child received ARV at birth (n = 1340) 0.3
None (reference) 6.5 1
NVP 4.5 0.7 0.2-2.2
Dual therapy 3.6 0.5 0.2-2.1
Don’t know 2.9 0.4 0.1-1.9
Mother delivered at health centre (n = 1336) 0.4
Yes 3.8 0.9 0.3-3.0
No (reference) 5.2 1
Feeding options at birth (n = 1303) 0.1
EBF (reference) 3.4 1
BF and early cessation 4.0 0.9 0.4-1.7
Formula 2.3 0.7 0.2-2.4
Animal modified milk 1.2 0.3 0.0-2.5
Number of ANC visits (n = 1340) 0.4
Less than four (reference) 4.3 1
Four or more 3.5 1.2 0.6-2.1
ARV and/or cotrimoxazole taken by the mother (n = 1333) 0.05
None (reference) 5.4 1
Cotrimoxazole 3.1 0.6 0.3-1.4
NVP alone 7.0 1.2 0.5-3.0
Dual therapy 4.8 1.1 0.4-3.0
Triple therapy 1.9 0.4 0.1-0.96*
Mother’s age (years) (n = 1337) 0.01*
15-24 (reference) 6.8 1
25-29 4.8 0.9 0.4-2.3
30-34 4.7 0.8 0.3-1.9
35-39 1.5 0.3 0.1-0.9
40-49 3.0 0.6 0.2-2.0
* Significant (p < 0.05 for univariate analysis); OR does not include 1 for multivariate analysis.
Table 4 Cumulative risk of HIV infection by 9-24 months and/or death by 9 months old among HIV-exposed children,
Rwanda PMTCT programme, 2009
Child’s outcome Total number of children assessed
& No % (95% CI) Yes % (95% CI)
Death 1455 95.8 (94.8-96.9) 4.2 (2.1-3.9)
HIV infection 1340 96.0 (95.0-.97.1) 4.0 (2.9-5.0)
HIV infection and/or death 1401 91.9* (90.4-.93.3) 8.1 (6.7-9.6)
&The total number of children assessed represents the population of HIV-exposed children assessed for each outcome
* The value in this cell estimates the proportion of children alive and free of HIV, defined as HIV-free survival by 9-24 months
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Page 6 of 11CI: 0.3-0.995) less likely to be infected with HIV and/or
dead compared with children whose mothers did not
receive any ARV during pregnancy (Table 5). Also, chil-
dren whose mothers received HAART for PMTCT were
(aOR: 0.6, 95% CI: 0.3-1.07) 40% less likely to have HIV
infection than living children whose mothers had not
received HAART (Table 6).
Discussion
This is, to our knowledge, the first evaluation of HIV-
free child survival in a national PMTCT programme in
a resource-limited setting. We reported a rate of HIV-
free survival of 91.9% among children born to HIV-posi-
tive mothers in the Rwanda national PMTCT pro-
gramme by nine to 24 months of age. This figure is
higher than the one reported at nine months (65-84%)
in an effectiveness evaluation of the PMTCT pro-
gramme that was limited to three districts in South
Africa [27]. However, the comparison between the two
evaluations is limited in that the South African evalua-
tion was conducted five years prior to the one in
Rwanda, at a time when single-dose nevirapine was the
only regimen used in South Africa.
Nevertheless, the nine- to 24-month HIV-free survival
rate in the Rwanda national PMTCT programme
remains comparable to the nine-month HIV-free survi-
val rate of 95% (91-97%) reported in a clinical trial con-
ducted in Rwanda in 2005-2007 comparing six months
of HAART during breastfeeding with formula feeding
[19]. Although the majority of women (83.3%) in our
study reported breastfeeding their child from birth com-
pared with 10.1% who provided formula, our HIV-free
survival rate at nine to 24 months is similar to the 12-
to 18-month HIV-free survival rate of 95% (91-97%)
reported in a recent evaluation of a district level
PMTCT demonstration programme providing a com-
prehensive package of health services, including free for-
mula from birth for all HIV-exposed infants [28]. Yet,
the national PMTCT programme in Rwanda does not
support provision of free formula for all HIV-exposed
children, instead promoting the implementation of the
WHO AFASS criteria [29] to determine the best feeding
option for each HIV-exposed infant. Our findings show
that infant feeding options at birth have an impact on
HIV-positive status; however, we do not have enough
statistical power to detect a difference.
The World Health Organization has reported that
HIV-free survival is related to the HIV MTCT rate and
survival regardless of HIV infection in a cohort of HIV-
exposed children [7]. It is a dynamic parameter that
decreases with time depending on the cumulative risk of
transmission (during exposure through breastfeeding),
access to HIV preventive methods during breastfeeding,
and access to the basic child survival package of interven-
tions. Based on the HIV prevalence among HIV-exposed
children (3.0%) and assuming that all reported child
deaths were HIV-positive cases (worst-case scenario), the
cumulative HIV transmission rate in the Rwanda national
PMTCT programme is estimated at 8.1% by nine to 24
months. This is likely to be an overestimation of the true
HIV transmission rate, given that exposure to HIV has
been recently reported to contribute to only 3.6% to 4%
of under-five mortality in sub-Saharan Africa [30,31].
Nevertheless, this is comparable with the cumulative HIV
transmission rate of 5.7% (95% CI: 2.5-9.0%) at 12
months from the MTCT-Plus Initiative in Abidjan, Cote
d’Ivoire, providing HAART or short-course ARV to HIV-
positive pregnant women for PMTCT [32].
Our study showed a 40% reduction in likelihood of
death or HIV infection by nine to 24 months when
mothers initiated HAART for PMTCT, consistent with
previous reports of increased HIV-free child survival
with use of maternal HAART initiated during pregnancy
and extended during breastfeeding [19,33,34]. Breast-
feeding with early cessation was reported by 33% of
HIV-positive mothers; however, mode of breastfeeding
was not associated with HIV-free survival in our study,
although previous randomized trials have provided evi-
dence of the negative impact of early and abrupt cessa-
tion of breastfeeding on HIV-free survival of children
[35,36]. The Rwandan Ministry of Health has already set
new national standards and guidelines for PMTCT in
line with the 2010 WHO guidelines [11], choosing the
option B regimen (every HIV-positive pregnant woman
will receive HAART as a lifelong treatment if eligible or
as prophylaxis until one week after cessation of breast-
feeding) [37].
Table 5 Factors associated with HIV-free survival among
HIV-exposed infants, Rwanda PMTCT programme, 2009
HIV-free survival
Adjusted odds
ratio
95% CI
ARV and/or cotrimoxazole taken by the
mother
None Reference 1
Cotrimoxazole 0.9 0.5-1.5
NVP alone 1.5 0.8-2.7
Dual therapy 0.6 0.3-1.5
Triple therapy 0.6 0.3-1.07
Location
Rural Reference 1
Urban 0.7 0.3-1.2
Membership of a PLHIV association, (n =
1417)
No Reference 1
Yes 0.7 0.4-
0.995
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Page 7 of 11Table 6 Prevalence of HIV infection among HIV exposed children according to socio-demographic characteristics
(mothers and children), Rwanda PMTCT programme, 2009
Characteristics HIV-positive
children
HIV-negative
children
Univariate
analysis (p)
Multivariate
analysis
OR 95%CI
Mothers characteristics
Mother’s age (years), % n = (1337) 0.01*
15-24 (reference) 6.8 93.2 1
25-29 4.8 95.2 0.7 0.3-1.8
30-34 4.7 95.3 0.6 0.2-1.5
35-39 1.5 98.5 0.2 0.1-0.8
40-49 3.1 96.9 0.4 0.1-1.4
Marital status,% n = (1336) 0.76
Single/never married (reference) 6.1 93.9 1
Married/cohabiting 3.4 96.6 0.7 0.3-2.1
Separated/divorced/widowed 4.3 95.7 1.3 0.4-4.2
Literacy,% n = 1338) 0.77
can’t or have difficult reading and/or writing (reference) 3.7 96.3 1
can read but can’t or have difficult writing 4.6 95.4 1.2 0.4-4.6
can read and write easily 4.1 95.9 0.9 0.5-1.8
Decision-making power in health and nutrition issues index
#, mean (SE)
(n = 1336)
89.4(2.8) 90.2 (0.5) 0.78 1.0 0.98-1.02
Decision-making power in short- and long-term investment strategies
index
#, mean (SE) (n = 1336)
82.1(3.8) 84.3(07) 0.54 0.9 0.98-1.01
Membership to a PLHIVassociation, % (n = 1323) 0.13
Yes 3.3 96.7 0.6 0.3-1.1
No (reference) 4.9 95.1 1
Household characteristics
Household size, mean (SE) (n = 1311) 5.0(0.36) 5.1(0.05) 0.57 1.0 0.8-1.1
Housing index
@, mean (SE) (n = 1313) 1.5(0.12) 1.4(0.02) 0.14 1.4 0.9-2.0
Household assets index
$, mean (SE) (n = 1329) 1.0(0.13) 0.9(0.03) 0.71 1.2 0.9-1.6
Access to clean water, % (n = 1323) 0.40
Yes 4.2 95.8 1.6 0.6-4.2
No (reference) 3.0 97.0 1
Location, % (n = 1340) 0.19
Rural 4.3 95.7 1
Urban 2.55 97.45 0.3 0.2-1.05
Children characteristics
Child’s sex (n = 1338) 0.89
Female (reference) 4.0 96.0 1
Male 3.9 96.1 0.8 0.5-1.7
Child’s age (months),% (n = 1340) 0.23
<=1 2 3.8 96.2 1
13-17 2.8 97.2 0.6 0.3-1.4
>1 8 5.1 94.9 1.2 0.6-2.5
* Significant p < 0.05
# Decision-making power about health and nutrition index is defined as a composite index created to measure the extent to which the respondent is involved in
making household decisions related to health and nutrition issues. Scores ranged from 0 to 100 and a higher score indicates greater decision-making power.
Decision-making power about short- and long-term investment strategies index is defined as a composite index created to measure the extent to which the
respondent is involved in making household decisions related to short and long-term investment issues.
@Housing material index is defined as a composite index indicating whether roof, walls, and floors of the respondent’s house are built in durable materials. The
index ranged from 0 to 3: 0 means that none of the housing materials are durable while 3 means that materials for roof, walls and floors are durable.
$ Household asset index is defined as a composite index indicating the number of valuable equipments owned (refrigerators, mobile telephone, radio, TV, car,
etc.).
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Page 8 of 11We reported in our study that 63% of HIV-positive
mothers had received any ARV during pregnancy, indi-
cating that more than one-third of women did not
receive ARV. More efforts will be required to increase
coverage and access to ARVs for mothers and children
as Rwanda transitions to option B [38] to improve both
maternal health and child survival. Other factors likely
to reduce barriers to access and utilization of these ser-
vices in Rwanda include: the community-based health
insurance covering 91% of households by 2010; the well-
functioning community health programme; and a
national system of performance-based financing for
health services [39].
Our study showed that psychological and social sup-
port systems organized for PLHIV were beneficial, redu-
cing by 30% the risk of death or HIV infection by nine
to 24 months among HIV-exposed children. Many stu-
dies have found a positive association between social
support and better health outcomes [40-42]. In a study
conducted among people living with HIV in the United
States of America, social support was found to be a
robust predictor of health outcomes over time, indepen-
dent of coping style and baseline medical status [43]. In
addition, the involvement of men in PMTCT has signifi-
cantly increased over the past five years in Rwanda to
reach 84% in 2009 (up from 33% in 2005), and has been
reported to significantly contribute to improved HIV-
free survival by 12 months [44].
Our study bears some limitations. We used a cross-
sectional design, and were not able to determine HIV
status of infants who had died prior to the survey. In
addition, recall bias may have occurred as mothers were
asked to report on events that had happened nine to 24
months earlier, including ARV treatment and HAART
regimens.
Another limitation of the study is the wide time inter-
val considered (nine to 24 months). Survival rates for
children who were one month old are different than
those at 24 months old; thus the timespan may cause an
overestimation or underestimation of survival rates.
Further, some of the children were still being breastfed
at the time of the interview. As such, these children
were still susceptible to infection and thus our probabil-
ity may be slightly underestimated.
A final limitation concerns the small number of
mother-child pairs who could not be found according to
the addresses given in the clinic rosters. Since all
mother-child pairs were replaced immediately if they
could not be located, our data do not include the num-
ber of pairs who were not included in the analysis due
to an inability to find them. Rwanda is launching a six-
week effectiveness study of the national PMTCT pro-
gramme in 2011 that will provide insights into early
HIV transmission rate, and estimate its association with
various factors that were not assessed in our study,
including maternal CD4 cell count.
Conclusions
Measuring the effectiveness of the national PMTCT
programme is imperative to determining the best course
of action at the country level, and to making better use
of the limited financial resources available. Rwanda is
leading the way and has reported a rate of HIV-free sur-
vival of 91.9% at nine to 24 months of age among HIV-
exposed children, a rate that can be further improved by
increasing access to HAART among HIV-positive preg-
nant women and by ensuring that women receive psy-
chological and social support from community-based
systems. As the world is gearing towards achieving the
goal of elimination of MTCT by 2015 [10], it is a strate-
gic imperative for national PMTCT programmes in sub-
Saharan Africa to assess the effectiveness of their
interventions
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